Array BioPharma, Inc. (NASDAQ:ARRY)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases.

Recs

2
Player Avatar 21popsontop (< 20) Submitted: 1/28/2010 10:21:53 AM : Outperform Start Price: $2.51 ARRY Score: -31.93

Has always had that longshot look, and now we see the big boys taking them out for dinner and paying for friendship, advise and technology expertise. Looks much better than DNDN for sure and even has real products on the market and several more in the oven. One to watch.

Featured Broker Partners


Advertisement